XNCR
$11.74
Xencor, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of engineered antibodies for the treatment of cancer and autoimmune diseases.
Recent News
Xencor (XNCR) Reports Q4 Loss, Tops Revenue Estimates
Xencor (XNCR) delivered earnings and revenue surprises of +86.00% and +30.62%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
Xencor: Q4 Earnings Snapshot
PASADENA, Calif. AP) — Xencor Inc. XNCR) on Wednesday reported a loss of $6.7 million in its fourth quarter.
What Catalysts Are Rewriting The Xencor (XNCR) Story In A Recovering Biopharma Sector
Xencor’s fair value estimate has been nudged up from about US$28.25 to roughly US$28.83 per share, with a slightly higher discount rate of around 7.50% and a modest lift in revenue growth assumptions to roughly 4.13%. These changes line up with a more supportive backdrop for U.S. biopharma, where stronger sector conditions, steadier deal activity and better access to capital are now being recognized in updated models, even as questions remain about how long these supports will hold. Stay...
Xencor (XNCR): BofA Bullish on US Biopharmaceuticals Coverage
Xencor Inc. (NASDAQ:XNCR) is one of the best high short interest stocks with biggest upside potential. On January 6, Bank of America raised its price target for Xencor to $20 from $17 while maintaining a Neutral rating. This sentiment was announced by the firm as part of its broader update to its US Biopharmaceuticals coverage. […]
Could Early XmAb819 Signals Reshape Xencor’s (XNCR) Broader T‑Cell Engager Investment Narrative?
In early January 2026, Xencor announced updated corporate priorities and 2026 pipeline milestones, highlighting new clinical data and advancement plans for multiple XmAb T-cell engager and autoimmune candidates across oncology and inflammatory diseases. A key development was the initial Phase 1 data for XmAb819 in advanced clear cell renal cell carcinoma, where a subset of efficacy-evaluable patients showed both tumor response and disease control, prompting plans for expansion cohorts and...